Elsevier

Metabolism

Volume 47, Supplement 1, December 1998, Pages 12-15
Metabolism

Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: A 3-year placebo-controlled biopsy study

https://doi.org/10.1016/S0026-0495(98)90364-XGet rights and content

Abstract

We conducted a 3-year randomized placebo-controlled double-blind study to determine the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril (PE) on the progress of renal function and histology in subjects with diabetes and microalbuminuria. Forty non—insulin-dependent (NIDDM) and insulin-dependent (IDDM) diabetic subjects, either normotensive or hypertensive, were randomly assigned to receive PE (n = 20) or placebo (n = 20). A percutaneous renal biopsy was performed initially in all patients and repeated in 29 patients after 3 years. The mean glomerular volume, glomerular basement membrane (GBM) thickness, interstitial fibrosis, sclerosed glomeruli, and volume fraction of capillary lumina were measured histomorphometrically. Before treatment, both groups had similar clinical characteristics, blood pressure, glycosylated hemoglobin (Hb), albumin excretion rate, glomerular filtration rate (GFR), serum creatinine, and renal structural damage. Blood pressure was well controlled in both groups. After 3 years' therapy, there was no significant change in renal function and albuminuria in the PE or placebo groups. The increase in GBM thickness in nine paired biopsies was significantly less in PE-treated subjects (P = .0275). Interstitial fibrosis tended to increase less in the PE group, although this did not reach statistical significance. This study indicates that long-term therapy with PE may decrease or delay the progression of structural glomerular damage in microalbuminuric diabetic subjects.

References (16)

There are more references available in the full text version of this article.

Cited by (56)

  • Exploring the binding interaction between bovine serum albumin and perindopril as well as influence of metal ions using multi-spectroscopic, molecular docking and DFT calculation

    2020, Chemical Physics
    Citation Excerpt :

    Perindopril have the characteristics of high trough-to-peak ratio (T/P), clinically effective, and weak adverse reactions in ACEIs. Some clinical trials also showed perindopril can reduce left ventricular hypertrophy and proteinuria in diabetic renal dysfunction, and improves arterial structure and function [17]. As far as we know, the study of the binding behavior of perindopril to SA has not been reported yet.

  • Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients with CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials

    2016, American Journal of Kidney Diseases
    Citation Excerpt :

    Table 1 summarizes characteristics of the included studies. There were 34 trials that compared ACE inhibitors to placebo,4-6,20-50 7 studies that compared ARBs to placebo,7,51-56 38 studies that compared ACE inhibitors with active controls,12,57-93 and 13 studies that compared ARBs with active controls.94-106 One study compared either ACE inhibitors or ARBs to active control,107 and 1 study compared ACE inhibitors with any antihypertensive treatment.108

  • Adherence and renal biopsy feasibility in the Renin Angiotensin-System Study (RASS) primary prevention diabetes trial

    2013, Diabetes Research and Clinical Practice
    Citation Excerpt :

    This a priori designed compliance ancillary study to the RASS provided an opportunity, in a primary prevention trial, to examine adherence patterns over time, including quantification of medication compliance, adherence to interval protocol tasks, as well as submission to the performance of a repeat renal biopsy. Whereas studies of participants with clinical renal disease have included repeated renal biopsies [28–31], to our knowledge this is the first native kidney sequential biopsy primary prevention trial with renal-asymptomatic diabetic participants. This approach was undertaken to study whether the investigational treatments could attenuate morphological changes associated with very early pathological disease progression.

  • Diabetic nephropathy

    2008, Molecular and Genetic Basis of Renal Disease
View all citing articles on Scopus

Supported by Servier Laboratories Australia.

View full text